Optimi Health increases MDMA quantities, bets on FDA approval

• Optimi Health has been granted the right to substantially increase the quantities of MDMA, MDA and 2CB
• The Vancouver-based company began increasing the dosage earlier this week after its Health Canada Controlled Drugs and Substances Licence amendment was approved
• Optimi intends to capitalize on this increase if MDMA consumption is approved by the U.S. Food and Drug Administration later this year
• Optimi Health stock closed at $0.30 per share

Optimi Health (CSE:OPTI) has been granted the right to substantially increase the quantities of MDMA, MDA and 2CB.

The Vancouver-based company began increasing the dosage earlier this week after its Health Canada Controlled Drugs and Substances Licence amendment was approved.

Quantity increases under Food and Drug regulations:

• N-methyl-3,4-methylenedioxy amphetamine (MDMA) – from 2 kg to 20 kg
• 3,4-methylenedioxyamphetamine (MDA) – from 1 kg to 2 kg
• 4-bromo-2,5-dimethoxybenzene ethanamine (2C-B) – from 400 g to 4 kg

“This marks a pivotal achievement in Optimi’s strategic licensing plan, positioning us with one of the most robust licensing portfolios globally. It enhances our competitive advantage and perfectly aligns with our vision to be the leading global supplier of GMP MDMA and other psychedelic substances,” Optimi CEO Bill Ciprick said in a news release.

Looking ahead, the company also pointed out that it intends to capitalize on this increase if MDMA consumption is approved by the U.S. Food and Drug Administration later this year.

Informational content guide Addiction Resource states that the standard recreational dose of MDMA (ecstasy) is 125 milligrams. According to research, a lethal dose of ecstasy for humans would be about 15 to 16 times that dose. Rollsafe advocates 1.5 mg/kg (with a max of 120 mg even if a person weighs more than 80 kg) for the entire session including booster doses.

Optimi has Health Canada approval to manufacture 18 controlled substances, including ketamine and psilocybin. The team has cultivated new psilocybin-containing mushroom strains with the aim that they will play a pivotal role in the development of psilocybin extracts and novel drug candidates. The new genetic strains were cultivated by Optimi’s cultivation manager, Scott Marshall, who oversees its large-scale operations, genetic advancement, and the stabilization of novel and existing varieties of psilocybe cubensis.

Optimi Health Corp. is a drug manufacturer and formulator licensed by Health Canada to produce and supply natural, GMP-grade psilocybin, synthetic psychedelic substances and functional mushrooms that focus on the health and wellness markets.

Optimi Health stock closed at $0.30 per share. Though its share price has declined nearly 22 per cent this week, it has risen almost 85 per cent over the past month and is up 27 per cent since this time last year.

Join the discussion: Find out what everybody’s saying about BlackBerry stock on the Optimi Health Corp. Bullboard and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.